PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the Bank of America Merrill Lynch Global Healthcare Conference 2024 in Las Vegas, NV on Wednesday, May 15 at 3:00 pm PT. To access the live webcast of BridgeBio's presentation, please visit the "Events & Presentations" page within the In ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38959 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 84-1850815 (State or other jurisdi ...

Exhibit 99.1 BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update - Presented cardiac magnetic resonance (CMR) imaging evidence consistent with clinical improvement observed in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in the ATTRibute-CM Phase 3 study of acoramidis at the American College of Cardiology Annual Scientific Sessions; additional detailed results from ATTRibute-CM are planned for presentation at 2024 medical meetings, including four abstracts accep ...

- Presented cardiac magnetic resonance (CMR) imaging evidence consistent with clinical improvement observed in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in the ATTRibute-CM Phase 3 study of acoramidis at the American College of Cardiology Annual Scientific Sessions; additional detailed results from ATTRibute-CM are planned for presentation at 2024 medical meetings, including four abstracts accepted for the European Society of Cardiology Heart Failure conference and eleven abstracts accept ...

- In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional improvement compared with placebo, with potential cardiac amyloid regression - The data demonstrate that targeting near-complete transthyretin (TTR) stabilization with acoramidis may enable cardiac remodeling and functional recovery in patients with ATTR-CM - These results are the first prospective, longitudinal evaluation of cardiac structure and function by CMR imaging in a double-blind ...

PALO ALTO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced the pricing on March 5, 2024 of an underwritten public offering of 8,620,690 shares of its common stock at a public offering price of $29.00 per share, before deducting underwriting discounts and commissions. In addition, BridgeBio has granted the underwriters a 30-day option to purchase up to an additi ...

- BridgeBio grants Bayer exclusive license to commercialize acoramidis as a treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in Europe - BridgeBio to receive royalties according to a tiered structure beginning in the low-thirties percent, designed to provide BridgeBio the opportunity to maximally share in the blockbuster potential of acoramidis - BridgeBio will also receive up to $310 Million USD in upfront and near-term milestone payments, and is eligible for additional undisclose ...

财务表现 - BridgeBio Pharma (BBIO)在2023年12月的季度报告中每股亏损为0.96美元，略低于Zacks Consensus预期的0.95美元[1] - 过去四个季度，公司未能超过市场预期的每股收益[2] - BridgeBio Pharma在2023年12月的季度营收为175万美元，较Zacks Consensus预期的187万美元低了74.53%[3] 股价走势 - 公司股价的短期走势将主要取决于管理层在财报电话会议上的评论[4]

Exhibit 99.1 BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update - Submitted New Drug Application (NDA) to US Food and Drug Administration (FDA) for acoramidis for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) based on positive results of Phase 3 ATTRibute-CM trial, which were published in the New England Journal of Medicine; NDA has been accepted for review with a PDUFA date of November 29, 2024; Marketing Authorization Application (MAA) for ac ...

新药申请和资本情况 - BridgeBio Pharma提交了新药申请(NDA)给美国食品和药物管理局(FDA)用于治疗转甲状腺激素淀粉样心肌病(ATTR-CM)[1] - NDA已被接受审查，PDUFA日期为2024年11月29日[1] - 公司从Blue Owl和CPP投资获得了高达12.5亿美元的资本[1] 财务状况 - 公司在2023年第四季度结束时拥有3.93亿美元的现金、现金等价物和短期受限制现金[1] - 公司在2023年第四季度的收入为1.7百万美元，全年收入为9.3百万美元[1] - 公司在2023年第四季度的运营成本和费用为1.79.2百万美元，全年为6.16.7百万美元[1] - 公司在2023年第四季度的股权补偿费用为3.71百万美元，全年为11.5百万美元[1] - 2023年度营收为9303千美元，较2022年度的77648千美元有所下降[22] - 2023年度研发、开发和其他费用为130824千美元，较2022年度的91549千美元增加了42.9%[22] - 2023年度股权报酬为37133千美元，较2022年度的22584千美元增加了64.6%[22] - 2023年度现金、现金等价物和可市场证券为375935千美元，较2022年度的428269千美元有所下降[23] - 2023年度净现金流出为527720千美元，较2022年度的419494千美元增加了25.8%[24] - 2023年度支付利息为61108千美元，较2022年度的54443千美元增加了12.2%[25] 公司业务和风险提示 - BridgeBio Pharma致力于发现、创造、测试和交付治疗遗传疾病和癌症的转化性药物[26] - 公司的前瞻性声明包括对产品候选药物的临床和治疗市场潜力的评估[27] - 公司的管理层对当前的计划、意图、期望和策略持乐观态度，但无法保证其实现[29] - 公司的前瞻性声明基于管理层的当前期望和信念，但受到一定风险和不确定性的影响[30]